Ensifentrine 

Unassigned

New Medicines

Chronic obstructive pulmonary disease (COPD)

Information

New molecular entity
Verona Pharma
Verona Pharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
None

Category

RPL554 is an innovative dual phosphodiesterease (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties
About 1.2 million people are affected by COPD in the UK. There are 115,000 new diagnoses a year. However, 60-85% of patients, mainly with mild-to-moderate disease, are thought to remain undiagnosed [9].
Chronic obstructive pulmonary disease (COPD)
Inhalation